Tumor Models

BioVenic provides comprehensive custom aquatic model services, including design, phenotyping, and analytical profiling for fish and invertebrates, to accelerate your physiological and drug discovery studies. Using aquatic organisms to model human biology and disease has become a powerful approach, offering unique evolutionary insights that complement mammalian systems. While these models hold great promise, their successful application depends on expert design and rigorous characterization, and that is exactly where BioVenic's tailored solutions come in, delivering precise, reliable data to move your research forward.

Strategic Research Programs We Accelerate

• Academic laboratories investigating fundamental tumor biology, cancer cell migration, and the genetic pathways of tumorigenesis.
• Pharmacology and biotech groups seeking rapid, high throughput screening platforms to evaluate anti-cancer therapeutic efficacy and toxicity.
• Environmental safety and toxicology teams assessing the direct impacts of water borne chemical pollutants and carcinogens on cancer development.

Fig 1. Generation and application of zebrafish models in cancer research.^1,3

Navigating Core Hurdles in Cancer Modeling

• High therapeutic screening bottlenecks: Shifting away from slow, costly mammalian assays toward rapid, high volume chemical and genetic validation platforms.
• Phenotypic tracking constraints: Utilizing the natural optical clarity of aquatic embryos to capture real-time, non-invasive tumor cell migration and metastasis in vivo.
• Adult transplantation barriers: Overcoming the traditional necessity for chemical immunosuppression to trace transplanted cancer cells over extended periods.
• Complex longitudinal tracking: Capturing the intricate progression of cancer evolution, cell cycle dynamics, and therapeutic resistance over developmental time.

Customized Aquatic Tumor Modeling Services

• Target Identification and Pathway Verification Services

Applicable Scenarios: Creating highly customized models to simulate specific human cancers and evaluate target gene function or regulatory pathways in vivo.

Technical Capabilities: We engineer custom aquatic models that express specific oncogenes or carry targeted tumor suppressor mutations to replicate clinical genetic landscapes.

Deliverables: Verified genomic sequence datasets, transcription abundance charts, target gene expression profiles, and initial pathway verification reports.

• High Throughput Drug Discovery and Screening Services

Applicable Scenarios: Rapidly evaluating the anti-tumor potential, anti-angiogenic effects, and metastatic inhibition of thousands of candidate compounds.

Technical Capabilities: Leveraging highly fertile, transparent embryos and larvae to perform real time visual screenings of candidate drug impacts on active tumor expansion and microvascular network formation.

Deliverables: Survival and mortality curves, high resolution fluorescent imaging sequences, compound efficacy comparison graphs, and therapeutic response datasets.

• Oncology Drug Optimization and Lead Development

Applicable Scenarios: Evaluating pharmacokinetic and pharmacodynamic parameters, testing formulation efficacy, and performing safety assessments to guide dose selection.

Technical Capabilities: We analyze target drug absorption, tissue distribution, metabolic processing, excretion, and overall adme parameters directly inside the model environment.

Deliverables: Toxicity profiling reports, absorption and metabolic concentration curves, tissue accumulation data, and dose selection guide dossiers.

• Preclinical Validation and Mechanism Studies

Applicable Scenarios: Confirming therapeutic efficacy, evaluating drug candidate actions, and investigating the complex tumor microenvironment.

Technical Capabilities: We perform in depth molecular analyses to elucidate how anti-cancer compounds affect tumor cells, surrounding vascular systems, and immune responses.

Deliverables: Complete mechanism of action reports, digital transcriptomic profiling dossiers, tumor microenvironment interaction maps, and ready to publish validation datasets.

Chronological Workflow from Model Design to Digital Delivery

Our systematic model development and characterization pipeline is optimized to deliver publication ready datasets and high fidelity translational insights.

1. Computational Design and Alignment: Performing in silico sequence alignments to verify genetic homology and select the optimal aquatic species for your human cancer target.
2. Model Target Induction: Utilizing customized chemical exposure, physical microinjection, or microenvironmental parameters to induce the target pathological cancer state.
3. Specialized Embryonic and Larval Rearing: Rearing induced cohorts in controlled, species optimized aquaculture systems to ensure uniform development and model reproducibility.
4. Optical Characterization and Imaging: Capturing high resolution, real-time tumor dynamics and morphological changes using advanced non-invasive fluorescent microscopy.
5. Molecular and Biochemical Profiling: Performing quantitative polymerase chain reaction assays, western blots, and enzymatic profiling to verify successful disease replication at the molecular level.
6. Comprehensive Data Dossier Delivery: Transferring the complete digital dataset including raw sequence files, high resolution imaging portfolios, quantitative metrics, and ready to publish assay protocols.

Why Choose BioVenic?

• Precision Genetic Modification: Deploying advanced site directed nucleases and active transposon systems to introduce targeted mutations or stable oncogenic transgenes into the host genome.
• Sequencing and Genomic Analysis: Confirming genomic integrity and transcript expression profiles utilizing high throughput Next generation Sequencing, Whole genome Sequencing, and transcriptomic RNA sequencing.
• High Resolution Imaging Technologies: Capturing real time cellular dynamics and cell cycle phases in vivo using confocal microscopy, two photon microscopy, light sheet microscopy, and micro computed tomography.

Strategic Applications of Aquatic Tumor Models

• Target Identification and Validation

Expressing custom oncogenes and mutating tumor suppressors to confirm functional therapeutic targets in vivo.

• High Throughput Screening

Deploying massive larval arrays to identify lead molecules, small compound libraries, and innovative biological candidates.

• Preclinical Optimization

Evaluating spatial drug localization, cellular metabolism, and systemic safety metrics before mammalian escalation.

• Environmental Carcinogenesis Research

Utilizing sentinel aquatic models to track how external carcinogens and toxins accelerate somatic tumor growth.

Published Data on Aquatic Tumor Models

Recent literature highlights the immense potential of automated screening systems for accelerating anti-cancer drug discovery. A key publication detailed the use of the ARQiv HTS platform to evaluate over half a million compound treated zebrafish (Danio rerio) larvae in a single screen. By arraying larvae in multi well plates, researchers simultaneously analyzed thousands of molecules in a whole organism context. This approach confirmed clear benefits including lower costs, ethical simplicity, and multi parameter endpoints like fluorescence quantification and tumor margin measurements. Although immersion delivery can present pharmacokinetic limitations for hydrophobic agents, optimizing digital dispensing and standardizing exposure paradigms significantly enhance data quality.

Fig 2. Zebrafish as a translational avatar for human cancer xenografts.^2,3

Frequently Asked Questions

1. How do your immunodeficient zebrafish models compare to traditional mammalian NSG mice for cancer research?
   Our immunodeficient zebrafish models, particularly double knockout prkdc deficient and il2rga deficient lines, engraft human cancers with similar growth kinetics and therapy responses as NSG mice. However, they offer much faster generation times, lower regulatory burdens, and optical transparency, which allows researchers to perform non-invasive real-time imaging of single cells that is impossible in mammalian systems.
2. How do you monitor single cell therapy responses and cell cycle progression in vivo?
   We utilize advanced fluorescent reporter cassettes such as the FUCCI4 system. By expressing distinct fluorescent markers at different stages of the cell cycle, our high resolution confocal and light sheet imaging systems can track G1, S, G2, and M phases in individual cancer cells in real time following drug treatments.
3. What initial specifications or materials must clients provide to launch a tumor modeling project?
   Clients only need to specify the target cancer type, preferred model species, human gene sequence or mutation details, and overall research goals. Our bioinformatics and veterinary pathology teams manage all subsequent guide design, vector construction, precision microinjection, and downstream analysis.

Partner with BioVenic

BioVenic is committed to advancing oncology and aquatic biological research with tailored aquatic animal tumor models. We recognize that standardized, stable tumor models are critical for tumor mechanism study, drug screening and therapeutic efficacy evaluation. Our experienced technical team delivers high-quality, customized aquatic tumor model construction to support your preclinical and fundamental research. To discuss your specific project requirements, explore our technical capabilities, or receive a detailed quote for your study, please contact us. Our experts are dedicated to providing reliable model solutions to drive your research forward.

Our products and services are for research use only and cannot be used for any clinical purposes.

Related Services